GRT-C903
AXP000162.1 · Cancer vaccine
- Platform
- chimpanzee adenovirus (ChAdV68, non-replicating)
- Originator
- Gritstone bio
- Sponsor
- Gritstone bio
Names
| Name | Type | Source |
|---|---|---|
| GRT-C903 | preferred name, code | curator, ncit |
| Shared Neoantigen Priming Cancer Vaccine GRT-C903 ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- chimpanzee adenovirus C68
- Strain
- ChAdV68
- Replication
- non replicating
- Modifications
- non-replicating great-ape adenovirus vector encoding a fixed cassette of shared tumour neoantigens
- Transgenes
- shared tumour neoantigens (incl. KRAS mutants)
- Route
- intramuscular
- Source
- evidence
Cross-references
- NCI Thesaurus
- C165514
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Active not recruiting | Phase 1 | 2024-05-16 | 2029-02-20 | 210 | Breast Cancer; Colorectal Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Metastatic Solid Cancers; Non-Small Cell Lung Cancer; Ovarian Cancer |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | Phase 1/2 | 2019-07-18 | 2023-03-10 | 39 | Colorectal Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer; Shared Neoantigen-Positive Solid Tumors; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38538867 | A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. | Nature medicine | 2024 | cited by trial NCT03953235 |
Notes
Shared-neoantigen ('off the shelf') adenoviral priming vaccine of Gritstone's SLATE regimen, boosted by the self-amplifying mRNA GRT-R904 (NCIt C165515, outside this pass). Phase 1/2 in KRAS-mutant and other shared-neoantigen solid tumours. Distinct cassette from the individualised GRT-C901 (AXP000161), hence a separate program.
How to cite
GRT-C903 (AXP000162.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000162.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.